Arvinas, Inc.
Arvinas, Inc. (Nasdaq: ARVN) is a clinical-stage biotechnology company developing medicines through its PROTAC protein-degradation platform, which is designed to harness the body’s protein-disposal system to remove disease-causing proteins. Its clinical programs address oncology and neurology: vepdegestrant targets… From the company’s description.
Over the twelve months to Sep 30, 2026, Arvinas, Inc. reported revenue of $275.30M, down 11.8% from a year earlier, and a net loss of $9.50M. Its operating margin was −12.1%, and operations used $158.30M in cash. In fiscal 2025, it reported revenue of $262.60M, down 0.3% from fiscal 2024, and a net loss of $80.80M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arvinas, Inc. does
In the company’s own words
Arvinas, Inc. (Nasdaq: ARVN) is a clinical-stage biotechnology company developing medicines through its PROTAC protein-degradation platform, which is designed to harness the body’s protein-disposal system to remove disease-causing proteins. Its clinical programs address oncology and neurology: vepdegestrant targets the estrogen receptor in advanced breast cancer; ARV-102 targets LRRK2 for neurodegenerative diseases including Parkinson’s disease; ARV-806 targets KRAS G12D in solid tumors; ARV-393 targets BCL6 in non-Hodgkin lymphoma; and ARV-027 targets expanded androgen receptor in skeletal muscle. The company also advances preclinical programs, including a HPK1 candidate and a pan-KRAS degrader, and conducts research collaborations with Pfizer and Genentech. Its intended beneficiaries are patients with cancer and neurological or neuromuscular diseases, with development and commercialization activities also involving collaborators and other third parties. The FDA has accepted the company’s application for vepdegestrant, its most advanced candidate, with an action date of June 5, 2026.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1655759
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arvinas, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arvinas, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arvinas, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arvinas, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arvinas, Inc.'s last four quarterly filings that the numbers alone won't show?”